Charles River Laboratories International (NYSE:CRL) EVP Sells $1,327,098.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 5,046 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,264,241. This represents a 51.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $266.95 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The business’s 50-day simple moving average is $214.85 and its two-hundred day simple moving average is $189.25. The stock has a market cap of $12.74 billion, a PE ratio of -55.04, a P/E/G ratio of 2.94 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $268.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRL. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after purchasing an additional 47,432 shares during the period. Eos Management L.P. bought a new stake in Charles River Laboratories International in the fourth quarter worth $839,000. Assetmark Inc. lifted its position in Charles River Laboratories International by 17.9% in the fourth quarter. Assetmark Inc. now owns 43,809 shares of the medical research company’s stock worth $8,739,000 after buying an additional 6,666 shares during the last quarter. Avidity Partners Management LP purchased a new position in Charles River Laboratories International during the first quarter worth $1,670,000. Finally, M&T Bank Corp increased its position in Charles River Laboratories International by 1,424.9% during the fourth quarter. M&T Bank Corp now owns 27,997 shares of the medical research company’s stock valued at $5,585,000 after acquiring an additional 26,161 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of a number of research analyst reports. Royal Bank Of Canada increased their price objective on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a report on Thursday. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Morgan Stanley upped their target price on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday. Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a research note on Thursday. Finally, Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $246.69.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.